93 related articles for article (PubMed ID: 8573379)
21. Differential antiviral activities and intracellular metabolism of 3'-azido-3'-deoxythymidine and 2',3'-dideoxyinosine in human cells.
Mukherji E; Au JL; Mathes LE
Antimicrob Agents Chemother; 1994 Jul; 38(7):1573-9. PubMed ID: 7526781
[TBL] [Abstract][Full Text] [Related]
22. Determination of zidovudine triphosphate intracellular concentrations in peripheral blood mononuclear cells from human immunodeficiency virus-infected individuals by tandem mass spectrometry.
Font E; Rosario O; Santana J; García H; Sommadossi JP; Rodriguez JF
Antimicrob Agents Chemother; 1999 Dec; 43(12):2964-8. PubMed ID: 10582890
[TBL] [Abstract][Full Text] [Related]
23. Quantitation of zidovudine triphosphate concentrations from human peripheral blood mononuclear cells by anion exchange solid phase extraction and liquid chromatography-tandem mass spectroscopy; an indirect quantitation methodology.
King T; Bushman L; Anderson PL; Delahunty T; Ray M; Fletcher CV
J Chromatogr B Analyt Technol Biomed Life Sci; 2006 Feb; 831(1-2):248-57. PubMed ID: 16412710
[TBL] [Abstract][Full Text] [Related]
24. Characterization of the anti-HIV-1 activity of 3,4-dihydro-2-alkoxy-6-benzyl-4-oxopyrimidines (DABOs), new non-nucleoside reverse transcriptase inhibitors.
Tramontano E; Marongiu ME; de Montis A; Loi AG; Artico M; Massa S; Mai A; la Colla P
New Microbiol; 1994 Oct; 17(4):269-79. PubMed ID: 7532270
[TBL] [Abstract][Full Text] [Related]
25. Genetic damage detected in CD-1 mouse pups exposed perinatally to 3'-azido-3'-deoxythymidine or dideoxyinosine via maternal dosing, nursing, and direct gavage: II. Effects of the individual agents compared to combination treatment.
Witt KL; Tice RR; Wolfe GW; Bishop JB
Environ Mol Mutagen; 2004; 44(4):321-8. PubMed ID: 15476197
[TBL] [Abstract][Full Text] [Related]
26. Synergistic inhibition of human immunodeficiency virus isolates (including 3'-azido-3'-deoxythymidine-resistant isolates) by foscarnet in combination with 2',3'-dideoxyinosine or 2',3'-dideoxycytidine.
Palmer S; Harmenberg J; Cox S
Antimicrob Agents Chemother; 1996 May; 40(5):1285-8. PubMed ID: 8723486
[TBL] [Abstract][Full Text] [Related]
27. The selective toxicity of medications used in the treatment of AIDS on the CEM human leukemic CD4+ T-cell line.
Coplan PM; Nolan LL
Drug Chem Toxicol; 1991; 14(3):257-64. PubMed ID: 1682133
[TBL] [Abstract][Full Text] [Related]
28. Uptake and distribution of 2',3'-dideoxyinosine and its derivatives in a human monocytoid cell line.
Vázquez-Padua MA; Mayol N; López M
Cell Mol Biol (Noisy-le-grand); 1995; 41 Suppl 1():S113-9. PubMed ID: 8574139
[TBL] [Abstract][Full Text] [Related]
29. Effect of lamivudine in HIV-infected persons with prior exposure to zidovudine/didanosine or zidovudine/zalcitabine.
Albrecht MA; Hughes MD; Liou SH; Katzenstein DA; Murphy R; Balfour HH; Para MF; Valdez H; Hammer SM;
AIDS Res Hum Retroviruses; 2000 Sep; 16(14):1337-44. PubMed ID: 11018853
[TBL] [Abstract][Full Text] [Related]
30. Relative mutagenic potencies of several nucleoside analogs, alone or in drug pairs, at the HPRT and TK loci of human TK6 lymphoblastoid cells.
Carter MM; Torres SM; Cook DL; McCash CL; Yu M; Walker VE; Walker DM
Environ Mol Mutagen; 2007; 48(3-4):239-47. PubMed ID: 17358029
[TBL] [Abstract][Full Text] [Related]
31. Immunotoxicity of 2',3'-dideoxyinosine in female B6C3F1 mice.
Phillips KE; McCay JA; Brown RD; Musgrove DL; Meade BJ; Butterworth LF; Wilson S; White KL; Munson AE
Drug Chem Toxicol; 1997 Aug; 20(3):189-228. PubMed ID: 9292277
[TBL] [Abstract][Full Text] [Related]
32. Pharmacokinetic interaction between intravenous 2',3'-dideoxyinosine and pentamidine in rats.
Yeh TK; Kang HJ; Wientjes MG; Au JL
Pharm Res; 1996 Apr; 13(4):628-32. PubMed ID: 8710758
[TBL] [Abstract][Full Text] [Related]
33. Inhibition of telomerase activity and cell proliferation by a reverse transcriptase inhibitor in gynaecological cancer cell lines.
Murakami J; Nagai N; Shigemasa K; Ohama K
Eur J Cancer; 1999 Jun; 35(6):1027-34. PubMed ID: 10533489
[TBL] [Abstract][Full Text] [Related]
34. Zidovudine phosphorylation and mitochondrial toxicity in vitro.
Sales SD; Hoggard PG; Sunderland D; Khoo S; Hart CA; Back DJ
Toxicol Appl Pharmacol; 2001 Nov; 177(1):54-8. PubMed ID: 11708900
[TBL] [Abstract][Full Text] [Related]
35. Relation of peripheral neuropathy to HIV treatment in four randomized clinical trials including didanosine.
Kelleher T; Cross A; Dunkle L
Clin Ther; 1999 Jul; 21(7):1182-92. PubMed ID: 10463516
[TBL] [Abstract][Full Text] [Related]
36. Zidovudine phosphorylation in HIV-infected patients and seronegative volunteers.
Barry M; Wild M; Veal G; Back D; Breckenridge A; Fox R; Beeching N; Nye F; Carey P; Timmins D
AIDS; 1994 Aug; 8(8):F1-5. PubMed ID: 7986398
[TBL] [Abstract][Full Text] [Related]
37. Combination therapy for patients with HIV-1 infection: the use of dual nucleoside analogues with protease inhibitors and other agents.
Gulick R
AIDS; 1998; 12 Suppl 3():S17-22. PubMed ID: 15168719
[TBL] [Abstract][Full Text] [Related]
38. Detection of human immunodeficiency virus type 1 clinical isolates with reduced sensitivity to zidovudine and dideoxyinosine by RNA.RNA hybridization.
Japour AJ; Chatis PA; Eigenrauch HA; Crumpacker CS
Proc Natl Acad Sci U S A; 1991 Apr; 88(8):3092-6. PubMed ID: 1707532
[TBL] [Abstract][Full Text] [Related]
39. Synergistic inhibition of human immunodeficiency virus replication in vitro by combinations of 3'-azido-3'-deoxythymidine and 3'-fluoro-3'-deoxythymidine.
Harmenberg J; Akesson-Johansson A; Vrang L; Cox S
AIDS Res Hum Retroviruses; 1990 Oct; 6(10):1197-202. PubMed ID: 1701316
[TBL] [Abstract][Full Text] [Related]
40. Pharmacokinetics of zidovudine phosphorylation in human immunodeficiency virus-positive thai patients and healthy volunteers.
Wattanagoon Y; Na Bangchang K; Hoggard PG; Khoo SH; Gibbons SE; Phiboonbhanakit D; Karbwang J; Back DJ
Antimicrob Agents Chemother; 2000 Jul; 44(7):1986-9. PubMed ID: 10858368
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
